815 results on '"Rifkin, Robert"'
Search Results
2. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry
3. A selective small-molecule agonist of G protein-gated inwardly-rectifying potassium channels reduces epileptiform activity in mouse models of tumor-associated and provoked seizures
4. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry
5. Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry
6. In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
7. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
8. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices
9. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
10. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry
11. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
12. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
13. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
14. OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
15. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
16. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
17. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites
18. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
19. Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
20. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
21. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study
22. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
23. Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?
24. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma
25. GIRK currents in VTA dopamine neurons control the sensitivity of mice to cocaine-induced locomotor sensitization
26. MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) After In-Class Transition (iCT) From Parenteral Bortezomib-Based Induction Therapy to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd): Data From the Phase 4, Community-Based US MM-6 Study (Fully Accrued Cohort)
27. MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)
28. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
29. Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
30. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
31. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
32. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
33. Exploring Antidepressant Adherence at a Student-Run Free Mental Health Clinic
34. MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study
35. P-285 Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connectmultiple myeloma disease registry
36. POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study
37. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
38. PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
39. Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology Centers
40. P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
41. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes
42. G Protein-Gated Potassium Channels: A Link to Drug Addiction
43. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
44. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
45. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
46. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
47. Safety and efficacy of biosimilars in oncology
48. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
49. Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
50. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.